2-<4-Acetamino-phenyl>-imidazo<1,2-a>pyridin | 103823-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-<4-Acetamino-phenyl>-imidazo<1,2-a>pyridin
• 英文别名: N-(4-imidazo[1,2-a]pyridin-2-yl-phenyl)-acetamide；acetic acid-(4-imidazo[1,2-a]pyridin-2-yl-anilide)；Essigsaeure-(4-imidazo[1,2-a]pyridin-2-yl-anilid)；N-(4-Imidazo[1,2-a]pyridin-2-ylphenyl)acetamide
• CAS: 103823-85-4
• 化学式: C₁₅H₁₃N₃O
• mdl: MFCD00431152
• 分子量: 251.288
• InChiKey: PKQGFWLOSGZMKR-UHFFFAOYSA-N

物化性质

• 熔点：
  245-246 °C(Solv: ethanol (64-17-5))
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-<4-Acetamino-phenyl>-imidazo<1,2-a>pyridin 以85%的产率得到
  参考文献：
  名称：

  SUNDBERG, RICHARD J.;DAHLHAUSEN, D. J.;MANIKUMAR, G.;MAVUNKEL, B.;BISWAS,+, J. HETEROCYCL. CHEM., 25,(1988) N 1, 129-137

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-硝基苯基)咪唑并[1,2-a]吡啶 在 镍 吡啶 、 氢气 作用下， 以 乙醇 、 氯仿 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 15.0h， 生成 2-<4-Acetamino-phenyl>-imidazo<1,2-a>pyridin
  参考文献：
  名称：

  2-芳基和2-芳氧基甲基咪唑并[1,2- a ]吡啶的制备及相关化合物

  摘要：

  一系列取代的2-芳基咪唑并[1,2-α]吡啶已被制备，其中多种取代基被引入在苯环的4'位和在3，5的，6或7位杂环。大多数实例在4'-位具有乙酰氨基，溴，氰基或甲酰基取代基。还已经制备了类似的咪唑并[ 2，1- b ]噻唑和咪唑并[1,2- a ]嘧啶。制备了由咪唑的4'-甲酰基苯氧基甲基衍生物，吡啶，噻唑，苯并咪唑和环取代的咪唑并[1,2- a ]吡啶的三个位置异构体组成的另一系列化合物。还制备了咪唑和咪唑并[1,2- a ]吡啶的2-（4'-甲酰基苯基乙烯基）衍生物。

  DOI：

  10.1002/jhet.5570250119

文献信息

• HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
  申请人：Ivaschenko Andrey Alexandrovich

  公开号：US20110053915A1

  公开（公告）日：2011-03-03

  The invention relates to novel heterocyclic compounds and to the use thereof, to pharmaceutical compositions containing said chemical compounds as an active ingredient and to the use thereof for producing medicinal preparations for the human being and warm-blood animals for treating diseases caused by the aberrant activity of an Hedgehog (Hh)-signal system, in particular oncological diseases. The invention also relates to the use of the above-mentioned compounds in the form of ‘molecular pharmacological tools’ for examining (in vitro and in vivo) the biochemical features of the Hh-signal system, in particular, the interaction of Hh protein and transmembrane proteins, namely, suppressor Patched (Ptc) and protooncogenic proteins. The eight groups of the claimed compounds comprise the derivatives of 2,6-dihydro-7H-pyrazolo[3,4-d]pyridazine-7-one and 1,4-dihydropyrazolo[3,4-b][1,4]thiazine-5-one; N-acidylated 4-imidazo[1,2-a]pyrimidine-2-il-anilines; ([4H-thino[3,2-b]pyrrol-5-il) carbonyl]piperidine-4-carbonic acid amides; 2-(4carbomoilpyperidine-1-il)-isonicotinic acid amides; N-sylphonyl-1,2,3,4-tetrahydroquinoline-6-carbonic acid amides; and pyridine 2-amino-4,5,6,7-tetrahydrothieno[2,3-c] N-acidylated 3-azole derivatives.

  该发明涉及新颖的杂环化合物及其用途，包括含有该化合物作为活性成分的药物组合物，以及用于制备用于治疗由Hedgehog（Hh）信号系统异常活性引起的人类和温血动物疾病的药物制剂。该发明还涉及上述化合物的使用形式为“分子药理学工具”，用于检查Hh信号系统的生化特征（体外和体内），特别是Hh蛋白与跨膜蛋白之间的相互作用，即抑制剂Patched（Ptc）和原癌基因蛋白。所述化合物的八个类别包括2,6-二氢-7H-吡唑并[3,4-d]吡啶嗪-7-酮和1,4-二氢吡唑并[3,4-b][1,4]噻嗪-5-酮的衍生物；N-酰化的4-咪唑并[1,2-a]嘧啶-2-基-苯胺；([4H-噻吩[3,2-b]吡咯-5-基)羰基]哌啶-4-羧酸酰胺；2-(4-羧甲基哌啶-1-基)-异尼古丁酸酰胺；N-磺酰基-1,2,3,4-四氢喹啉-6-羧酸酰胺；以及吡啶2-氨基-4,5,6,7-四氢噻吩[2,3-c] N-酰化的3-唑衍生物。
• ANTITUMOR DERIVATIVES FOR DIFFERENTIATION THERAPY
  申请人：THE CLEVELAND CLINIC FOUNDATION

  公开号：US20170253589A1

  公开（公告）日：2017-09-07

  Imidazopyridine derivatives according to formula I are described wherein X is selected from CH, N, S, and O, Y is selected from S, CO, and O, R 1 and optional R 2 are independently selected from H, OH, substituted or unsubstituted C 1 -C 6 alkyl, and substituted or unsubstituted C 4 -C 6 cycloalkyl or cycloheteroalkyl, R 3 is selected from H, OH, substituted or unsubstituted C 1 -C 6 alkyl, and optional Z is selected from OH, NH 2 , NH(CO)R 4 , NH(SO 2 )R 4 , guanidine, alkylguanidine, and fluoroguanidine, R 4 is polyethylene glycol or substituted or unsubstituted C 1 -C 6 alkyl, and pharmaceutically acceptable salt thereof. The imidazopyridine derivatives can be used for treatment of cancer in a subject.

  根据公式I描述的咪唑吡啶衍生物，其中X选自CH、N、S和O，Y选自S、CO和O，R1和可选的R2分别选自H、OH、取代或未取代的C1-C6烷基，以及取代或未取代的C4-C6环烷基或环杂烷基，R3选自H、OH、取代或未取代的C1-C6烷基，可选的Z选自OH、NH2、NH(CO)R4、NH(SO2)R4、胍、烷基胍和氟代胍，R4为聚乙二醇或取代或未取代的C1-C6烷基，及其药用盐。这些咪唑吡啶衍生物可用于治疗受试者的癌症。
• Au-catalyzed domino process synthesis of imidazo[1,2-a]pyridines from 2-aminopyridine and N-tosylhydrazones: An efficient C N bond formation reaction
  作者：Pengfeng Guo、Shuyu Huang、Jiaxian Mo、Xiaoyan Chen、Hangqi Jiang、Weifeng Chen、Hehuan Cai、Haiying Zhan

  DOI：10.1016/j.catcom.2016.10.033

  日期：2017.2

  A novel Au-catalyzed domino reaction for the synthesis of imidazo[1,2-a]pyridines from 2-aminopyridine and N-tosylhydrazones has been developed using molecular oxygen. It represents a new strategy for the formation of CN bonds. This transformation demonstrated a broad tolerance toward the substrates and allowed the generation of a diverse imidazo[1,2-a]pyridine derivatives with good yields.

  利用分子氧开发了一种新的金催化的多米诺骨牌反应，该反应由2-氨基吡啶和N-甲苯磺酰hydr合成咪唑并[1,2- a ]吡啶。它代表了形成C N键的新策略。该转化显示出对底物的广泛耐受性，并允许以良好的产率产生多种咪唑并[1,2- a ]吡啶衍生物。
• Antitumor derivatives for differentiation therapy
  申请人：THE CLEVELAND CLINIC FOUNDATION

  公开号：US10370373B2

  公开（公告）日：2019-08-06

  Imidazopyridine derivatives according to formula I are described wherein X is selected from CH, N, S, and O, Y is selected from S, CO, and O, R1 and optional R2 are independently selected from H, OH, substituted or unsubstituted C1-C6 alkyl, and substituted or unsubstituted C4-C6 cycloalkyl or cycloheteroalkyl, R3 is selected from H, OH, substituted or unsubstituted C1-C6 alkyl, and optional Z is selected from OH, NH2, NH(CO)R4, NH(SO2)R4, guanidine, alkylguanidine, and fluoroguanidine, R4 is polyethylene glycol or substituted or unsubstituted C1-C6 alkyl, and pharmaceutically acceptable salt thereof. The imidazopyridine derivatives can be used for treatment of cancer in a subject.

  根据式 I 描述了咪唑吡啶衍生物 其中 X 选自 CH、N、S 和 O，Y 选自 S、CO 和 O，R1 和任选的 R2 独立选自 H、OH、取代或未取代的 C1-C6 烷基和取代或未取代的 C4-C6 环烷基或环杂环烷基，R3 选自 H、OH、取代或未取代的 C1-C6 烷基，任选 Z 选自 OH、NH2、NH(CO)R4、NH(SO2)R4、胍、烷基胍和氟胍，R4 是聚乙二醇或取代或未取代的 C1-C6 烷基，以及它们的药学上可接受的盐。咪唑吡啶衍生物可用于治疗受试者的癌症。
• 10.1080/10426507.2024.2349305
  作者：Kaya, Betül、Yurttaş, Leyla、Baysal, Merve、Korkut Çelikateş, Büşra、Kaplancıklı, Zafer Asım、İmamoğlu, Rizvan

  DOI：10.1080/10426507.2024.2349305

  日期：——

  Here we report the synthesis and anticancer activities of fourteen novel imidazo[1,2-a]pyridine derivatives (6a-6n) containing S-alkyl/aryl moiety. The target compounds were obtained via a six-step...

  在这里，我们报道了十四种新型含S-烷基/芳基部分的咪唑并[1,2-a]吡啶衍生物(6a-6n)的合成和抗癌活性。目标化合物通过六步获得...